Wasatch Advisors LP Has $11.34 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

Wasatch Advisors LP increased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 37.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,488,493 shares of the biopharmaceutical company's stock after buying an additional 952,691 shares during the period. Wasatch Advisors LP owned 5.56% of MacroGenics worth $11,338,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC boosted its holdings in shares of MacroGenics by 1,230.1% during the third quarter. FMR LLC now owns 137,215 shares of the biopharmaceutical company's stock worth $451,000 after acquiring an additional 126,899 shares during the period. Stifel Financial Corp boosted its stake in MacroGenics by 19.7% in the 3rd quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company's stock valued at $131,000 after purchasing an additional 6,578 shares during the period. Wellington Management Group LLP boosted its stake in MacroGenics by 15.7% in the 3rd quarter. Wellington Management Group LLP now owns 307,140 shares of the biopharmaceutical company's stock valued at $1,010,000 after purchasing an additional 41,733 shares during the period. XTX Topco Ltd acquired a new position in MacroGenics in the 3rd quarter valued at $37,000. Finally, Barclays PLC increased its position in MacroGenics by 97.1% during the 3rd quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company's stock worth $325,000 after buying an additional 48,639 shares during the period. Institutional investors and hedge funds own 96.89% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MGNX. StockNews.com cut shares of MacroGenics from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright cut their price objective on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, March 25th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $7.38.

MacroGenics Stock Up 2.1 %

Shares of MGNX traded up $0.03 during midday trading on Tuesday, hitting $1.42. The company's stock had a trading volume of 153,562 shares, compared to its average volume of 1,131,742. MacroGenics, Inc. has a one year low of $0.99 and a one year high of $16.59. The stock has a market capitalization of $89.52 million, a price-to-earnings ratio of -0.90 and a beta of 2.23. The company's fifty day simple moving average is $1.90 and its two-hundred day simple moving average is $2.89.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The company had revenue of $49.40 million during the quarter, compared to the consensus estimate of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. On average, research analysts predict that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.